CNCR vs. CANC

Last updated Apr 2, 2026

Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and Tema Oncology ETF (CANC).

CNCR and CANC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.

Performance

CNCR vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

CNCR vs. CANC - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
CANC Tema Oncology ETF	1.48%

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: 1.16%
• 1M: -0.89%
• YTD: 6.91%
• 6M: 27.17%
• 1Y: 58.38%
• 3Y*: 140.92%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. CANC - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than CANC's 0.75% expense ratio.

CNCR

Loncar Cancer Immunotherapy ETF

CANC

Tema Oncology ETF

Return for Risk

CNCR vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 92
CANC Sharpe Ratio Rank: 92
CANC Sortino Ratio Rank: 92
CANC Omega Ratio Rank: 86
CANC Calmar Ratio Rank: 95
CANC Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.04	—

Dividends

CNCR vs. CANC - Dividend Comparison

CNCR has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.

	TTM	2025	2024	2023
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%

Drawdowns

CNCR vs. CANC - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for CNCR and CANC.

Drawdown Indicators

	CNCR	CANC	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-97.53%	+97.53%
Max Drawdown (1Y) Largest decline over 1 year	—	-12.40%	—
Current Drawdown Current decline from peak	0.00%	-55.68%	+55.68%
Average Drawdown Average peak-to-trough decline	0.00%	-73.89%	+73.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.57%	—

Volatility

Volatility by Period

	CNCR	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	8.20%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.22%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	27.19%	-27.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	285.53%	-285.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	285.53%	-285.53%